Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, March 2000, p. 760-762, Vol. 44, No. 3
Département de Microbiologie
Médicale et Moléculaire, Centre Hospitalier Universitaire
Bretonneau, 37044 Tours cedex,1 and
Service de Bactériologie, Hôpital Cochin
(Université Paris V), 75679 Paris cedex
14,2 France
Received 9 June 1999/Returned for modification 2 September
1999/Accepted 29 November 1999
A plasmid-encoded extended-spectrum TEM The dissemination of antibiotic
resistance is a clear example of gene exchange between distantly
related bacteria (13). However, this phenomenon is rare
enough that the presence of a TEM (This work was presented at the 98th General Meeting of the American
Society for Microbiology, Atlanta, Ga., 17 to 21 May 1998.)
C. ochracea CIP 105321 was isolated in 1996 at Bretonneau
Hospital Tours, France, from a culture of blood from an 11-year-old child with acute myeloid leukemia, fever (39°C), severe neutropenia, and oral mucositis who had received an empiric antibiotic
treatment, including ceftazidime. The
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Capnocytophaga ochracea: Characterization of a
Plasmid-Encoded Extended-Spectrum TEM-17
-Lactamase in the
Phylum Flavobacter-Bacteroides
![]()
ABSTRACT
Top
Abstract
Text
References
-lactamase with a pI of
5.5 was detected in a Capnocytophaga ochracea clinical
isolate. The bla gene was associated with a strong TEM-2
promoter and was derived from blaTEM-1a with a
single-amino-acid substitution: Glu104
Lys, previously
assigned to TEM-17, which is thus the first TEM
-lactamase to be
reported in the phylum Flavobacter-Bacteroides.
![]()
TEXT
Top
Abstract
Text
References
-lactamase in Capnocytophaga
ochracea, a Cytophagale belonging to the phylum
Flavobacter-Bacteroides (14), is of note, this type of enzyme being previously described only in the very
phylogenetically distant Proteobacteria (4, 17,
22). C. ochracea is a capnophilic gram-negative fusiform rod with gliding motility. It is part of the
normal gingival flora in humans and causes gingivitis and periodontitis. It may cause systemic infections in immunocompromised and neutropenic patients (11). Antibiotic treatment was
originally based on its susceptibility to penicillins, including
benzylpenicillin (7). The organism was later shown to be
susceptible to extended-spectrum cephalosporins, making it possible to
prescribe these drugs (2). Enzymatic resistance to
-lactams, including extended-spectrum cephalosporins, was
reported as early as 1986 in clinical isolates of C. ochracea (3, 8, 18, 19). The genetic basis of resistance was not determined for any of the resistant strains. We
report for the first time a plasmid-encoded TEM extended-spectrum
-lactamase in a clinical isolate of C. ochracea.
-lactamase reaction
in the nitrocefin-disk test (Cefinase; bioMérieux, Marcy
l'Etoile, France) was positive. The disk-agar diffusion test performed
on chocolate agar containing 1% PolyVitex (bioMérieux) showed
that strain CIP 105321 was resistant to penams (amoxicillin,
ticarcillin, and piperacillin) and cephems (cephalothin,
cefoperazone, cefuroxime, cefotaxime, ceftazidime, ceftriaxone,
cefpirome, and cefepime), but susceptible to cefoxitin, aztreonam,
piperacillin-tazobactam, and imipenem. There was extensive synergy
between amoxicillin-clavulanic acid and
-lactam disks, including
those for all extended-spectrum cephalosporins tested. The strain
was also resistant to gentamicin, polymyxin B, and cotrimoxazole,
as commonly reported in the genus Capnocytophaga (7, 19). MICs were determined by agar dilution on
Wilkins-Chalgren agar (Difco, Detroit, Mich.) with an inoculum of
104 CFU per spot (3, 18). The MICs of the two
-lactamase inhibitors, clavulanic acid and sulbactam, were found to
be 0.6 and 0.8 µg/ml, respectively. To prevent an intrinsic
antibacterial effect of clavulanate and sulbactam, a concentration of
0.1 µg/ml (if combined with a
-lactam) was then used for all
plates. The strain was resistant to amoxicillin (MIC, 512 µg/ml), had
intermediate resistance to piperacillin (MIC, 32 µg/ml), and was
more resistant to ceftazidime (MIC, 64 µg/ml) than to cefpirome,
cefepime, and cefotaxime (MIC, 16 µg/ml). It was susceptible to
imipenem and cefoxitin, as was the
-lactamase-negative control
strain, CIP 103448. Clavulanic acid and sulbactam partly restored the
activity of amoxicillin, cefotaxime, and ceftazidime (Table
1).
TABLE 1.
In vitro susceptibility of C. ochracea strains
to antibiotics
Three types of crude
-lactamase extract were prepared. Lysis by
sonication and by Triton treatment was performed as previously described (8). For lysis by both sonication and detergent, 4% Triton X-100 was added to the sonicated cells. The
-lactamase activity of the supernatants was estimated by the iodine procedure in
gels containing benzylpenicillin, by comparing the decolorized zones
obtained with that for a sonicated extract containing TEM-1
-lactamase (6).
-Lactamase activity was not detected
in a 24-h broth culture or a Triton extract. Weak activity was detected in a sonicated extract, and strong activity was obtained if Triton was
added after sonication. The analytical isoelectric focusing method used
was adapted from that described by Foweraker et al. (8),
with polyacrylamide gels containing ampholines (Pharmacia, Uppsala,
Sweden) with a pH range of 3.5 to 9.5. Focusing of the enzyme could
only be achieved for extracts containing Triton and if 4% Triton was
included in the gel. This was previously reported to be the case for
two other
-lactamases in Capnocytophaga, possibly due to
enzyme binding to membrane components (8, 18). The
-lactamase migrated as a single band with an estimated pI of 5.5 in
comparisons with known
-lactamases (TEM-1, pI 5.4; TEM-3, pI
6.3; and TEM-4, pI 5.9).
Plasmid DNA isolated by alkaline lysis was about 9 kb in size. Plasmid
curing was done by culture with ethidium bromide and replica plating
(6). The cured clones were highly susceptible to all
-lactams tested (Table 1) and did not produce
-lactamase detectable by the nitrocefin test on colonies. Resistance to other antimicrobial agents was not affected.
PCR was performed with plasmid DNA as the template and a
pair of primers (Eurogentec, Seraing, Belgium), 1079 [5'-d(GGTCTGACAGTTACCAATGC)-3'] and 6 [5'-d(GAAGACGAAAGGGCCTCGTG)-3'], internal to
blaTEM-1, with nucleotide
positions given according to the numbering of Sutcliffe (21). Both strands of the PCR product were sequenced by
automated fluorescent sequencing with an ABI Prism 377 sequencer
(Perkin-Elmer), by using Thermo Sequenase dye terminator cycle
sequencing premixed version 2.0 (Amersham, Les Ulis, France). Analysis
of the nucleotide sequence (Table
2) showed that the gene encoding
C. ochracea
-lactamase differed from the
blaTEM-1a gene by four silent mutations (positions 469, 682, 863, and 985) and that there was a
Glu104
Lys amino acid substitution in the protein
according to the numbering scheme of Ambler et al. (1, 9).
Lys104 substitution is common in extended-spectrum
-lactamases derived from TEM-1 or TEM-2 enzymes and is always
associated with one to three additional amino acid changes at positions
21, 153, 164, 182, 237, 238, 240, and 265 (15;
http://www.lahey.org/studies/webt.htm). The presence of
single mutation Glu104
Lys has already been suspected on
the basis of colony hybridization with specific oligonucleotide probes (oligotyping) in a single strain of Klebsiella pneumoniae.
The enzyme was called TEM-17 (12). After sequencing of
the corresponding gene, the deduced amino acid sequence was identical
to that of TEM-15, and the enzyme was therefore redesignated TEM-15
(10). Because the
-lactamase of C. ochracea
CIP 105321 presents the single Glu104
Lys amino acid
substitution, we assigned it the number TEM-17
(http://www.lahey.org/studies/webt.htm). As for most of these enzymes,
the blaTEM-17 gene was associated with a strong
TEM-2 promoter with a C-to-T substitution at nucleotide 32 that
increases the amount of enzyme (5).
|
It is not clear how Capnocytophaga acquired a
blaTEM gene. Given the probable emergence in
1986 of the first isolates of Capnocytophaga producing
extended-spectrum
-lactamases and the small size of the plasmids
involved, the donating strain probably transferred the
extended-spectrum
-lactamase gene via a transposon. However, Capnocytophaga may have acquired the
blaTEM-1 gene via a transposon or small plasmid
and then modified the blaTEM-1 gene by point mutation to give blaTEM-17, possibly due to
selection pressure exerted by the extended-spectrum cephalosporins used
to treat neutropenic patients. The ecological niche of
Capnocytophaga and the small size of the plasmid involved
suggest that the donating strain was of the genus
Haemophilus or Neisseria, in which TEM extended-spectrum
-lactamases have never been reported. The TEM-1
-lactamase should therefore also be present in
Capnocytophaga strains.
In conclusion, the emergence of such inactivating enzymes in the Flavobacter-Bacteroides phylum at the same time as in the very distant Proteobacteria phylum (16, 20) requires further molecular investigation to trace the movements of the blaTEM gene.
Nucleotide sequence accession number. The nucleotide sequence of blaTEM-17 has been assigned accession no. Y14574 in the EMBL Nucleotide Sequence Database.
| |
ACKNOWLEDGMENTS |
|---|
We thank M. Kiredjian, Laboratoire des Identifications Bactériennes, Institut Pasteur Paris, France, for the identification at the species level of the Capnocytophaga strain.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Département de Microbiologie Médicale et Moléculaire, EA2639, Centre Hospitalier Universitaire Bretonneau, 2 Bd Tonnelé, 37044 Tours cedex, France. Phone: 33 247478059. Fax: 33 247473812. E-mail: rosenau{at}med.univ-tours.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Ambler, R. P.,
A. F. W. Coulson,
J. M. Frère,
J. M. Ghuysen,
B. Joris,
M. Forsman,
R. C. Levesque,
G. Tiraby, and S. G. Waley.
1991.
A standard numbering scheme for the class A -lactamases.
Biochem. J.
276:269-272.
|
| 2. |
Arlet, G.,
M. J. Sanson-Le Pors,
I. M. Casin,
M. Ortenberg, and Y. Perol.
1987.
In vitro susceptibility of 96 Capnocytophaga strains, including a -lactamase producer, to new -lactam antibiotics and six quinolones.
Antimicrob. Agents Chemother.
31:1283-1284 |
| 3. |
Arlet, G.,
M. J. Sanson-Le Pors,
S. Castaigne, and Y. Perol.
1987.
Isolation of a strain of -lactamase-producing Capnocytophaga ochracea.
J. Infect. Dis.
155:1346[Medline].
|
| 4. |
Bush, K.,
G. A. Jacoby, and A. A. Medeiros.
1995.
A functional classification scheme for -lactamases and its correlation with molecular structure.
Antimicrob. Agents Chemother.
39:1211-1233[Medline].
|
| 5. |
Chen, S.-T., and R. C. Clowes.
1987.
Variations between the nucleotide sequences of Tn1, Tn2, and Tn3 and expression of -lactamase in Pseudomonas aeruginosa and Escherichia coli.
J. Bacteriol.
169:913-916 |
| 6. | Courvalin, P., F. Goldstein, A. Philippon, and J. Sirot (ed.). 1985. L'antibiogramme. MPC-Vidéom, Paris, France. |
| 7. |
Forlenza, S. W.,
M. G. Newman,
A. L. Horikoshi, and U. Blachman.
1981.
Antimicrobial susceptibility of Capnocytophaga.
Antimicrob. Agents Chemother.
19:144-146 |
| 8. |
Foweraker, J. E.,
P. M. Hawkey,
J. Heritage, and H. W. Van Landuyt.
1990.
Novel -lactamase from Capnocytophaga sp.
Antimicrob. Agents Chemother.
34:1501-1504 |
| 9. | Goussard, S., and P. Courvalin. 1991. Sequence of the genes blaT-1B and blaT-2. Gene 102:71-73[CrossRef][Medline]. |
| 10. |
Goussard, S., and P. Courvalin.
1999.
Updated sequence information for TEM -lactamase genes.
Antimicrob. Agents Chemother.
43:367-370 |
| 11. | Kristensen, B., H. C. Schønheyder, N. A. Peterslund, S. Rosthøj, N. Clausen, and W. Frederiksen. 1995. Capnocytophaga (Capnocytophaga ochracea group) bacteremia in hematological patients with profound granulocytopenia. Scand. J. Infect. Dis. 27:153-155[Medline]. |
| 12. |
Mabilat, C., and P. Courvalin.
1990.
Development of "oligotyping" for characterization and molecular epidemiology of TEM -lactamases in members of the family Enterobacteriaceae.
Antimicrob. Agents Chemother.
34:2210-2216 |
| 13. | Maiden, M. C. J. 1998. Horizontal genetic exchange, evolution, and spread of antibiotic resistance in bacteria. Clin. Infect. Dis. 27:S12-S20. |
| 14. |
Nakagawa, Y., and K. Yamasato.
1996.
Emendation of the genus Cytophaga and transfer of Cytophaga agarovorans and Cytophaga salmonicolor to Marinilabilia gen. nov.: phylogenetic analysis of the Flavobacterium-Cytophaga complex.
Int. J. Syst. Bacteriol.
46:599-603 |
| 15. |
Palzkill, T., and D. Botstein.
1992.
Identification of amino acid substitutions that alter the substrate specificity of TEM-1 -lactamase.
J. Bacteriol.
174:5237-5243 |
| 16. |
Paul, G. C.,
G. Gerbaud,
A. Bure,
A. M. Philippon,
B. Pangon, and P. Courvalin.
1989.
TEM-4, a new plasmid-mediated -lactamase that hydrolyzes broad-spectrum cephalosporins in a clinical isolate of Escherichia coli.
Antimicrob. Agents Chemother.
33:1958-1963 |
| 17. |
Philippon, A.,
S. Ben Redjeb,
G. Fournier, and A. Ben Hassen.
1989.
Epidemiology of extended spectrum -lactamases.
Infection
17:347-354[CrossRef][Medline].
|
| 18. |
Roscoe, D. L.,
S. J. V. Zemcov,
D. Thornber,
R. Wise, and A. M. Clarke.
1992.
Antimicrobial susceptibilities and -lactamase characterization of Capnocytophaga species.
Antimicrob. Agents Chemother.
36:2197-2200 |
| 19. |
Rummens, J. L.,
B. Gordts, and H. W. Van Landuyt.
1986.
In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents.
Antimicrob. Agents Chemother.
30:739-742 |
| 20. |
Sirot, D.,
J. Sirot,
R. Labia,
A. Morand,
P. Courvalin,
A. Darfeuille-Michaud,
R. Perroux, and R. Cluzel.
1987.
Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel -lactamase.
J. Antimicrob. Chemother.
20:323-334 |
| 21. |
Sutcliffe, J. G.
1978.
Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322.
Proc. Natl. Acad. Sci. USA
75:3737-3741 |
| 22. |
Woese, C. R.
1987.
Bacterial evolution.
Microbiol. Rev.
51:221-271 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |